Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tariquidar methanesulfonate, hydrate is a potent and specific P-glycoprotein (P-gp) inhibitor(Kd of 5.1 nM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 10,900 | 待询 |
Tariquidar methanesulfonate, hydrate 的其他形式现货产品:
产品描述 | Tariquidar methanesulfonate, hydrate is a potent and specific P-glycoprotein (P-gp) inhibitor(Kd of 5.1 nM). |
靶点活性 | P-gp:(kd)5.1 nM |
体外活性 | Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent P-gp mediated [3H]-Vinblastine modulator and [3H]-Paclitaxel transport as it increases the steady-state accumulation of these cytotoxics in CHrB30 cells to levels observed in non-P-gp-expressing AuxB1 cells with EC50 of 487±50 nM. [3H]-Tariquidar binds to CHrB30 membranes with the highest affinity with Kd of 5.1±0.9 nM, n=7 and a binding capacity (Bmax) of 275±15 pmol/mg membrane protein. In contrast to the parental cell line, the accumulation of [3H]-Vinblastine is increased in a dose-dependent fashion by the modulators XR9576 with EC50 of 487±50 nM. The MDR modulator Tariquidar is able to inhibit 60-70% of the vanadate-sensitive ATPase activity(IC50 of 43±9 nM)[1]. Tariquidar potentiates the cytotoxicity of several drugs including Doxorubicin, Paclitaxel, Etoposide, and Vincristine; complete reversal of resistance is achieved in the presence of 25-80 nM Tariquidar. Tariquidar is a potent inhibitor of photoaffinity labeling of P-gp by [3H]Azidopine implying a direct interaction with the protein[2]. |
体内活性 | In mice with intrinsically resistant MC26 colon tumors, co-administration of hydrated Tariquidar mesylate (XR9576 mesylate, hydrate) can enhance the antitumor activity of doxorubicin without significantly increasing toxicity; maximum potentiation is observed at 2.5-4.0 mg/kg dosed either i.v. or p.o. In addition, coadministration of Tariquidar (6-12 mg/kg p.o.) fully restores the antitumor activity of Paclitaxel, Etoposide, and Vincristine against two highly resistant MDR human tumor xenografts (2780AD, H69/LX4) in nude mice. Tariquidar is found to also significantly potentiate the antitumor activity of doxorubicin against s.c. MC26 tumors in vivo[2]. |
别名 | XR9576 methanesulfonate, hydrate |
分子量 | 892.99 |
分子式 | C40H52N4O15S2 |
CAS No. | 625375-83-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 296 mg/mL (331.47 mM)
H2O: 5 mg/mL (5.60 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 1.1198 mL | 5.5992 mL | 11.1983 mL | 27.9958 mL |
5 mM | 0.224 mL | 1.1198 mL | 2.2397 mL | 5.5992 mL | |
DMSO | 10 mM | 0.112 mL | 0.5599 mL | 1.1198 mL | 2.7996 mL |
20 mM | 0.056 mL | 0.28 mL | 0.5599 mL | 1.3998 mL | |
50 mM | 0.0224 mL | 0.112 mL | 0.224 mL | 0.5599 mL | |
100 mM | 0.0112 mL | 0.056 mL | 0.112 mL | 0.28 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tariquidar methanesulfonate, hydrate 625375-83-9 Others XR9576 methanesulfonate, hydrate Tariquidar methanesulfonate, Hydrate XR9576 methanesulfonate, Hydrate Inhibitor inhibitor inhibit